4
Total investments
0
Early stage
2
Mid stage
1
Late stage
23y
Years active
Portfolio
3 investments · sorted by recency
All investments
Early stage
Mid stage
Late stage
Private investor and shareholder
Jan 2011
CENTOGENE’s mission is to provide data-driven, life-changing answers to patients, physicians, and pharma companies for rare and neurodegenerative diseases. We integrate multiomic technologies with the CENTOGENE Biodatabank – providing dimensional analysis to guide the next generation of precision medicine. Our unique approach enables rapid and reliable diagnosis for patients, supports a more precise physician understanding of disease states, and accelerates and de-risks targeted pharma drug discovery, development, and commercialization.
Largest privat investor and shareholder
Jan 2011
CENTOGENE’s mission is to provide data-driven, life-changing answers to patients, physicians, and pharma companies for rare and neurodegenerative diseases. We integrate multiomic technologies with the CENTOGENE Biodatabank – providing dimensional analysis to guide the next generation of precision medicine. Our unique approach enables rapid and reliable diagnosis for patients, supports a more precise physician understanding of disease states, and accelerates and de-risks targeted pharma drug discovery, development, and commercialization.
CEO and Investor
2003
ProBioGen AG is a renowned Contract Development and Manufacturing Organization (CDMO) and technology provider. We perform cell line engineering, process development, and GMP manufacturing of biopharmaceuticals for clients in biotech and pharma. We offer proprietary innovative technologies for optimized biopharmaceutical manufacturing and analysis. ProBioGen also provides process development services and manufacturing technologies for viral vaccines.
Our additional new building houses 1000 L single-use bioreactor capacity to keep up with the ever-increasing demand from our clients. A second 1000 L single-use bioreactor is coming soon.
With over 25 years of experience in animal cell culture, combined with innovative scientific excellence and a strong intellectual property base, we cover the entire drug development value chain end-to-end.
Experience · 9 entries
All (9)
Investments (4)
Founder (3)
2022
Chairman Supervisory Board and Co-Founder
Jan 2022
Arcensus is an innovative start-up healthcare company dedicated to the early medical diagnosis of all genetic diseases and dispositions. We are exclusively focussing on the currently most innovative method for genetic diagnostics, whole genome sequencing. Our special expertise is the comprehensive and scientific in-depth bioinformatic pipeline analysis and handling of the resulting big data sets and their use for a better understanding of biology and medical principles. Modern healthcare systems are moving from the diagnosis of present medical problems towards their prevention. We will contribute to this with our international team of scientists and experts. Add genomics to your health and be our next colleague and partner.
2019
S
schlenkCONSULT GbR
Founder and Owner
Oct 2019
2014
CEO and Investor
Oct 2014
curasan develops, manufactures and markets biomaterials and medical devices in the field of bone and tissue regeneration, wound healing and osteoarthritis therapy. As a pioneer and global technology leader in the growing field of regenerative medicine, curasan is specialized primarily on biomimetic bone grafting materials for dental, oral/maxillofacial, orthopedic and spinal applications.
Numerous patents and a broad record of scientific publications demonstrate the clinical success of curasan´s highly innovative products. Dental and orthopedic clinicians worldwide benefit from the broad range of the premium quality and easy to use portfolio offered by the technology leader curasan.
curasan maintains its own high-tech facilities for research, development and manufacturing of biomaterials in Frankfurt/Main, Germany. In addition to its headquarters, the company has a subsidiary, curasan, Inc., in Wake Forest, near Raleigh, N.C., USA.
curasan´s innovative products are cleared by the US Food and Drug Administration (FDA) and many other international authorities. curasan´s products are available in over 50 countries worldwide.
Imprint: www.curasan.de/impressum
2011
Private investor and shareholder
Jan 2011
CENTOGENE’s mission is to provide data-driven, life-changing answers to patients, physicians, and pharma companies for rare and neurodegenerative diseases. We integrate multiomic technologies with the CENTOGENE Biodatabank – providing dimensional analysis to guide the next generation of precision medicine. Our unique approach enables rapid and reliable diagnosis for patients, supports a more precise physician understanding of disease states, and accelerates and de-risks targeted pharma drug discovery, development, and commercialization.
Largest privat investor and shareholder
Jan 2011
CENTOGENE’s mission is to provide data-driven, life-changing answers to patients, physicians, and pharma companies for rare and neurodegenerative diseases. We integrate multiomic technologies with the CENTOGENE Biodatabank – providing dimensional analysis to guide the next generation of precision medicine. Our unique approach enables rapid and reliable diagnosis for patients, supports a more precise physician understanding of disease states, and accelerates and de-risks targeted pharma drug discovery, development, and commercialization.
Show all 9 entries ↓
Investment activity
2003–2014 · 4 investments
Recent (last 2 years)Earlier
Similar investors
Biotechnology investors in Germany
Investor lists
Lists that match Michael's portfolio
- Biotechnology investors in Germany260 investors
- Startup investors in Germany2,001 investors






